Table 1.
Demographics and General Clinical Characteristics of Patients With Genital Psoriasis at Baseline.
| Characteristic | All Patients (N = 65) |
|---|---|
| Age (years) | 50.4 (14.2%) |
| Male sex | 46 (70.8%) |
| BMI (kg/m2) | 26.7 (5.6%) |
| Comorbidities | |
| • Psoriatic Arthritis | 6 (9.2%) |
| • Obesity | 14 (21.5%) |
| • Type 2 diabetes | 5 (7.7%) |
| • Hyperlipidemia | 10 (15.4%) |
| • Hypertension | 15 (23.1%) |
| • Cardiovascular diseases | 3 (4.6%) |
| Previous SARS-CoV-2 infection | 19 (29.2%) |
| Mean age at baseline (years) | 48.2 (14.9) |
| Mean duration of psoriasis (years) | 13.9 (11.3) |
| Psoriasis on special locations | |
| • Genital | 65 (100%) |
| • Scalp | 48 (73.8%) |
| • Palmo-plantar | 19 (29.2%) |
| • Nails | 25 (38.5%) |
| Mean PASI at baselinea | 18.3 (9.0%) |
| Mean DLQI at baseline a | 17.1 (8.8%) |
| Previous exposure to biologics | 25 (38.5%) |
| Adalimumab | 12 (18.5%) |
| Brodalumab | 1 (1.5%) |
| Ixekizumab | 2 (3.1%) |
| Risankizumab | 2 (3.1%) |
| Secukinumab | 9 (13.8%) |
| Tildrakizumab | 1 (1.5%) |
| Ustekinumab | 3 (4.6%) |
BMI = body mass index; DLQI = Dermatology Life Quality Index; PASI: Psoriasis Area and Severity Index.
a
PASI and DLQI scores were available for 63 patients at baseline. Continuous variables were reported as mean (standard deviation), while categorical variables were expressed as absolute number (percentage).